StreetInsider.com News Articles

H.C. Wainwright Starts Talphera (TLPH) at Buy

Fri, 05 Jun 2026 06:50:59 -0400

(Updated - June 5, 2026 6:50 AM EDT)

H.C. Wainwright analyst Brandon Folkes initiates coverage on Talphera (NASDAQ: TLPH) with a Buy rating.

The analyst comments "We are assuming coverage of Talphera, Inc. with a Buy rating and $3 price target. TLPH is developing Niyad, a lyophilized formulation of nafamostat, as a regional anticoagulant for the extracorporeal circuit in continuous renal replacement therapy, or CRRT. We view the risk reward in TLPH as favorable from current levels given the company’s ~$53MM market capitalization, $200MM+ U.S. peak sales opportunity across CRRT and intermittent hemodialysis, and a registrational NEPHRO CRRT study that we believe

H.C. Wainwright Starts Talphera (TLPH) at Buy

Fri, 05 Jun 2026 06:50:59 -0400

(Updated - June 5, 2026 6:50 AM EDT)

H.C. Wainwright analyst Brandon Folkes initiates coverage on Talphera (NASDAQ: TLPH) with a Buy rating.

Form 4 TALPHERA, INC. For: May 20 Filed by: Aslam Shakil

Thu, 21 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26536544.html

Form 4 TALPHERA, INC. For: May 20 Filed by: Aslam Shakil

Thu, 21 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260521/26536544.html

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: LYTTON LAURENCE W

Fri, 15 May 2026 13:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26503109.html

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: LYTTON LAURENCE W

Fri, 15 May 2026 13:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26503109.html

Form 10-Q TALPHERA, INC. For: Mar 31

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486781.html

Form 10-Q TALPHERA, INC. For: Mar 31

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486781.html

Talphera (TLPH) Misses Q1 EPS by 4c

Wed, 13 May 2026 16:20:37 -0400

Talphera (NASDAQ: TLPH) reported Q1 EPS of ($0.04).

For earnings history and earnings-related data on Talphera (TLPH) click here.

Form 8-K TALPHERA, INC. For: May 13

Wed, 13 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26486059.html

Form 8-K TALPHERA, INC. For: May 13

Wed, 13 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26486059.html

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:05:00 -0400

NEPHRO CRRT clinical study expected to be completed this year

Cash and investments of $21.1 million at March 31, 2026

Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET

"In early March, we announced the attainment of 50% enrollment in the

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Tue, 12 May 2026 13:23:00 -0400

si-local-file:///var/storage/secattach/20260512/26476468.html

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Tue, 12 May 2026 13:23:00 -0400

si-local-file:///var/storage/secattach/20260512/26476468.html

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Thu, 07 May 2026 16:05:00 -0400

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessed here or by visiting the Investors section

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Thu, 07 May 2026 16:05:00 -0400

Webcast Information

The webcast can be accessed here or by visiting the Investors section

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Thu, 07 May 2026 16:05:00 -0400

Webcast Information

The webcast can be accessed here or by visiting the Investors section

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Thu, 07 May 2026 16:05:00 -0400

Webcast Information

The webcast can be accessed here or by visiting the Investors section